Patents Assigned to Rosetta-Genomics
-
Patent number: 8389486Abstract: Described herein are compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids.Type: GrantFiled: January 25, 2008Date of Patent: March 5, 2013Assignees: Rosetta Genomics, Ltd, Immune Disease InstituteInventors: Judy Lieberman, Francisco Navarro
-
Publication number: 20120295962Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: May 25, 2012Publication date: November 22, 2012Applicants: ROSETTA GENOMICS LTD., REGULUS THERAPEUTICS INC.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric G. Marcusson, Noga Yerushalmi
-
Publication number: 20120232124Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: ApplicationFiled: July 20, 2010Publication date: September 13, 2012Applicant: Rosetta Genomics LtsInventors: Ayelet Chajut, Shai Rosenwald
-
Patent number: 8236939Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: GrantFiled: February 8, 2010Date of Patent: August 7, 2012Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 8211867Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: October 29, 2008Date of Patent: July 3, 2012Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric G. Marcusson, Noga Yerushalmi
-
Patent number: 8207316Abstract: The present invention relates to a group of noel viral RNA regulatory genes, here identified as “viral genomic address messenger genes”or “VGAM genes”, and as “Viral genomic record”or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a pervasive viral attack mechanism. VGR genes encode an “operon”-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: October 30, 2003Date of Patent: June 26, 2012Assignee: Rosetta Genomics, Inc.Inventor: Itzhak Bentwich
-
Patent number: 8163896Abstract: The present invention relates to a first group of novel genes, here identified as genomic address messenger or GAM genes, and a second group of novel operon-like genes, here identified as genomic record or GR genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 200 GAM genes, and 1096 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: November 24, 2003Date of Patent: April 24, 2012Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 8084598Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as genomic address messenger or GAM oligonucleotides, and a second group of novel operon-like polynucleotides, here identified as genomic record or GR polynucleotides. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 2147 GAM oligonucleotides, and 313 GR polynucleotides as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotide and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: January 29, 2004Date of Patent: December 27, 2011Assignee: Rosetta Genomics Inc.Inventor: Itzhak Bentwich
-
Patent number: 8039608Abstract: The present invention relates to a group of novel human genes, here identified as “genomic address messengers” or “GAM”. GAM genes selectively inhibit translation of known “target” genes, many of which are known to be involved in various diseases. Several nucleic acid molecules are provided respectively encoding several GAM genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for selectively enhancing translation of the respective target genes, and for detecting expression thereof.Type: GrantFiled: August 13, 2003Date of Patent: October 18, 2011Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Publication number: 20110251150Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 29, 2008Publication date: October 13, 2011Applicants: Rosetta Genomics Ltd.Inventors: C. Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20110229894Abstract: The invention relates to methods for detecting an altered susceptibility to breast and ovarian cancer in a subject carrying a BRCA mutation, comprising determining the nucleic acid sequence of a polymorphism of a microRNA-related gene.Type: ApplicationFiled: November 30, 2009Publication date: September 22, 2011Applicants: ROSETTA GENOMICS LTD., TEL HASHOMER MEDICAL INFRASTRUCTURE AND SERVICES L TD.Inventors: Asaf Levy, Eitan Freidman
-
Publication number: 20110223656Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: ApplicationFiled: September 23, 2009Publication date: September 15, 2011Applicant: Rosetta GenomicsInventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 7943754Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various bacterial infections. Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 24, 2004Date of Patent: May 17, 2011Assignee: Rosetta-GenomicsInventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7906326Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as genomic address messenger or GAM oligonucleotides, and a second group of novel operon-like polynucleotides, here identified as genomic record or GR polynucleotides. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 1708 GAM oligonucleotides, and 246 GR polynucleotides as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotide and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: February 16, 2004Date of Patent: March 15, 2011Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7888497Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 14, 2004Date of Patent: February 15, 2011Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7842800Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: April 2, 2004Date of Patent: November 30, 2010Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7825229Abstract: Described are polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.Type: GrantFiled: May 4, 2006Date of Patent: November 2, 2010Assignee: Rosetta Genomics Ltd.Inventors: Bentwich Itzhak, Amir Avniel, Yael Karov, Ranit Aharonov
-
Publication number: 20100267814Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 29, 2008Publication date: October 21, 2010Applicants: REGULUS THERAPEUTICS INC., ROSETTA GENOMICS LTD.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric G. Marcusson, Noga Yerushalmi
-
Patent number: 7795419Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.Type: GrantFiled: August 28, 2006Date of Patent: September 14, 2010Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 7790867Abstract: The present invention relates to a group of viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: August 28, 2003Date of Patent: September 7, 2010Assignee: Rosetta Genomics Inc.Inventor: Itzhak Bentwich